Neurotrope, Inc. announced the appointment of Larry D. Altstiel, M.D., Ph.D. to the company's Board of Directors, effective September 12, 2014. The appointment of Dr. Altstiel fills a vacancy on the Board of seven members. Dr. Altstiel will also become Chairman of the Nominating and Corporate Governance Committee and a member of the Audit and Compensation Committees of the Board.

He is also a member of Neurotrope's Scientific Advisory Board, a position he has held since October 2013. In addition to his roles at Neurotrope, since 2013, Dr. Altstiel is Chief Executive Officer of Provectra Therapeutics Inc. Prior to Provectra, from 2007 to 2013, Dr. Altstiel was Vice President Neuroscience Clinical Development, Neuroscience Therapeutic Area Clinical Lead, at Pfizer, Inc.